Abeona Therapeutics (NASDAQ:ABEO) Issues Earnings Results, Beats Estimates By $0.11 EPS

Abeona Therapeutics (NASDAQ:ABEO) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.11, Zacks reports.

Abeona Therapeutics Stock Performance

Abeona Therapeutics stock traded up $0.06 during midday trading on Thursday, reaching $5.26. 156,082 shares of the company traded hands, compared to its average volume of 302,795. The firm has a market capitalization of $228.66 million, a price-to-earnings ratio of -1.96 and a beta of 1.79. The business has a 50 day moving average of $5.47 and a two-hundred day moving average of $5.83. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $8.45. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Analyst Ratings Changes

ABEO has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday, February 19th. Oppenheimer initiated coverage on shares of Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, StockNews.com cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 22nd. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.